INDUSTRY NEWS
NICE GUIDANCE WELCOMED
Allergan plc has welcomed the publication of NICE guidance recommending the use of OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) for an important group of patients with diabetic macular oedema (DME).
“This guidance from NICE confirms the value of OZURDEX® as a treatment for DME, and supports its use as a clinically relevant and cost effective option for patients with this condition,†said Sara Vincent, Senior Vice President and Allergan UK Country Manager. www.allergan.com
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.